Jump to content


From Wikipedia, the free encyclopedia
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
Targetstaphylococcal lipoteichoic acid
Clinical data
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass146072.36 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.[1][2]


  1. ^ Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. (July 2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668. PMID 19380597.
  2. ^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov